Altre lingue Rocket Pharmaceuticals, Inc.

Azioni

RCKT

US77313F1066

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
21,98 ^USD	-0,54%		-3,60%	-26,66%

16/04	L'insider di Rocket Pharmaceuticals ha venduto azioni per un valore di 1.945.785 dollari, secondo un recente deposito SEC	MT
11/04	L'insider di Rocket Pharmaceuticals ha venduto azioni per un valore di 308.763 dollari, secondo un recente documento della SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	16/04
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	11/04
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	02/04
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02/04
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02/04
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO	26/03
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team	26/03
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer	26/03
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	26/03
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?	05/03
Rocket Pharmaceuticals Q4 Loss Narrows	26/02
Rocket Pharmaceuticals: Q4 Earnings Snapshot	26/02
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	26/02
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26/02
North American Morning Briefing : S&P 500 Futures -2-	23/02
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I	14/02
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	13/02
FDA Extends Review of Rocket Pharma's Proposed Kresladi	13/02
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)	13/02
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	13/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Rocket Pharmaceuticals, Inc.

Azioni

RCKT

US77313F1066

Altre lingue

Filtri